42.5 D
Mots-C
Also known as: Mitochondrial ORF of the 12S rRNA type-c
Emerging Research Research Chemical
Research Evidence 20.0/100
Safety Profile 65.0/100
7 Clinical Trials
Unknown: 3 PHASE2: 1 NA: 3
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination Unknown Phase RECRUITING University of Athens
- Cohort Of DEafness-gene Screening Unknown Phase ACTIVE_NOT_RECRUITING Affiliated Hospital of Nantong University
- Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD Unknown Phase UNKNOWN University of Athens
- MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity PHASE2 RECRUITING Hudson Biotech
- Analysis of Effects of High-intensity Physical Exercise in Subjects With Dialyzed Chronic Kidney Disease and in Conservative Treatment NA RECRUITING Casa di Cura Dott. Pederzoli
Showing 5 of 7 trials.
20 Research Papers
- Muscle-Targeted Nanocomposite Therapy Alleviates Age-Related Sarcopenia via Antioxidant and Metabolic Reprogramming. ACS Nano unknown
- MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free Radic Biol Med unknown
- Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models. Naunyn Schmiedebergs Arch Pharmacol unknown
- Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy. Int J Biol Macromol Review
- Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free Radic Biol Med unknown
Showing 5 of 20 papers by citation count.
FDA Data
Not FDA-Approved
Mots-C has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is Mots-C FDA approved?
No, Mots-C has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has Mots-C been studied in?
Mots-C has been studied in 7 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Mots-C?
Mots-C has a CheckPeptides trust score of 42.5/100 (grade: D). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 8, 2026
Quick Facts
- Classification
- Mitochondria-derived peptide
- Molecular Weight
- 2174.6 Da
- PubChem
- CID 176489569 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 20.0/100
Safety Profile 65.0/100
Evidence Summary
- Clinical Trials
- 7
- Research Papers
- 20
- Trust Score
- 42.5/100
- Grade
- D